Trial Profile
Active-Controlled, Double-Blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Procter & Gamble
- 01 Feb 2009 Results have been published in Clinical Therapeutics.
- 13 Feb 2008 New trial record.
- 06 Jun 2006 Results have been presented at the International Osteoporosis Foundation World Congress on Osteoporosis.